MXPA01008006A - Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles - Google Patents
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehiclesInfo
- Publication number
- MXPA01008006A MXPA01008006A MXPA/A/2001/008006A MXPA01008006A MXPA01008006A MX PA01008006 A MXPA01008006 A MX PA01008006A MX PA01008006 A MXPA01008006 A MX PA01008006A MX PA01008006 A MXPA01008006 A MX PA01008006A
- Authority
- MX
- Mexico
- Prior art keywords
- vehicle
- formulation
- beneficial agent
- stable
- viscous
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 114
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 93
- 238000009472 formulation Methods 0.000 claims abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 25
- 229940079593 drugs Drugs 0.000 claims abstract description 17
- 230000036760 body temperature Effects 0.000 claims abstract description 15
- 239000003981 vehicle Substances 0.000 claims description 99
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 39
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 39
- 229920000642 polymer Polymers 0.000 claims description 18
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 150000001298 alcohols Chemical class 0.000 claims description 11
- 239000002687 nonaqueous vehicle Substances 0.000 claims description 10
- 230000002035 prolonged Effects 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 230000003078 antioxidant Effects 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 229920001400 block copolymer Polymers 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 230000001954 sterilising Effects 0.000 claims description 5
- LQZZUXJYWNFBMV-UHFFFAOYSA-N Dodecanol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 4
- 229940068965 Polysorbates Drugs 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 claims description 3
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 claims description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
- 229940075579 Propyl Gallate Drugs 0.000 claims description 3
- 229960001295 Tocopherol Drugs 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 102000004965 antibodies Human genes 0.000 claims description 3
- 108090001123 antibodies Proteins 0.000 claims description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 229930003799 tocopherols Natural products 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- 229940089114 Drug Delivery Device Drugs 0.000 claims description 2
- 229940088597 Hormone Drugs 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N Propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 150000004040 pyrrolidinones Chemical class 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical group CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- 229950008882 Polysorbate Drugs 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 46
- 102000002265 Human Growth Hormone Human genes 0.000 description 27
- 108010000521 Human Growth Hormone Proteins 0.000 description 27
- 239000000854 Human Growth Hormone Substances 0.000 description 27
- 241000048284 Potato virus P Species 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 239000000843 powder Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 229920001983 poloxamer Polymers 0.000 description 13
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 10
- -1 lauryl lactate Chemical class 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- ARIWANIATODDMH-UHFFFAOYSA-N Monolaurin Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000004059 degradation Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 241001427367 Gardena Species 0.000 description 4
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- 230000002459 sustained Effects 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 102100008873 POMC Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000001603 reducing Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- ADNPLDHMAVUMIW-CUZNLEPHSA-N (2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-y Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- DGCPIBPDYFLAAX-NFVVVWSGSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[2-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-h Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 DGCPIBPDYFLAAX-NFVVVWSGSA-N 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001289 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001866 Atrial natriuretic peptide Proteins 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 108010031578 Beta-endorphin Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 229940019700 Blood coagulation factors Drugs 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N Bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- CMXXGAYYYTUFAY-UHFFFAOYSA-N CCCCCCCCCCCCC(OC(=O)CCCCCCCCCCC)C(O)CO Chemical compound CCCCCCCCCCCCC(OC(=O)CCCCCCCCCCC)C(O)CO CMXXGAYYYTUFAY-UHFFFAOYSA-N 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Enkephalin L Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 229950001491 Fertirelin Drugs 0.000 description 1
- 101700002119 GAL Proteins 0.000 description 1
- 101710042131 GCG Proteins 0.000 description 1
- 229940068939 GLYCERYL MONOLAURATE Drugs 0.000 description 1
- 102100000899 GNRH1 Human genes 0.000 description 1
- 101700071595 GRZ1 Proteins 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229960004666 Glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 229960002913 Goserelin Drugs 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 108060005045 Motilin Proteins 0.000 description 1
- XLXSAKCOAKORKW-KPKRHBJMSA-N N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl] Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-KPKRHBJMSA-N 0.000 description 1
- 101710008235 NTS Proteins 0.000 description 1
- 229940053128 Nerve Growth Factor Drugs 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102100017240 OXT Human genes 0.000 description 1
- 101710008205 OXT Proteins 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 Oxytocin Drugs 0.000 description 1
- 102100002857 PDYN Human genes 0.000 description 1
- 108060006375 POMC Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229960000553 Somatostatin Drugs 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 102100002996 TAC1 Human genes 0.000 description 1
- 101700065588 TAC1 Proteins 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 Triacetin Drugs 0.000 description 1
- 229960004824 Triptorelin Drugs 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 102100005236 ZGLP1 Human genes 0.000 description 1
- 101700078733 ZGLP1 Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 108010041395 alpha-Endorphin Proteins 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical class [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000000368 destabilizing Effects 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 102000035362 glycosylated proteins Human genes 0.000 description 1
- 108091005600 glycosylated proteins Proteins 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- PCJGZPGTCUMMOT-UHFFFAOYSA-N neurotensin Chemical compound C1CCN(C(=O)C(CCCNC(N)=N)NC(=O)C(CCCNC(N)=N)NC(=O)C2N(CCC2)C(=O)C(CCCCN)NC(=O)C(CC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C2NC(=O)CC2)C1C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 PCJGZPGTCUMMOT-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 101700057139 oxyT Proteins 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UWEYRJFJVCLAGH-UHFFFAOYSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C21F UWEYRJFJVCLAGH-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 239000012087 reference standard solution Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- NXSIJWJXMWBCBX-NWKQFZAZSA-N α-Endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 NXSIJWJXMWBCBX-NWKQFZAZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N β-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
Abstract
This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1 x 107 reciprocal second.
Description
VISCOUS VEHICLES, SINGLE PHASE, NON-AQUEOUS, STABLE AND FORMULATIONS USING SUCH VEHICLES
FIELD OF THE INVENTION This invention relates to viscous, biocompatible, single-phase, non-aqueous, stable vehicles capable of suspending beneficial agent and uniformly dispensing said agents at low flow rates, and more particularly, to mixed formulations. uniformly, stable, beneficial agents in viscous, biocompatible, single-phase, non-aqueous, stable vehicles.
References The following citations are referenced by the numbers in co hetes ([]) in the relevant portion of the specification. 1. Wang, et al., J. Parenteral Sci. Tech, 42: S4-S26 (1988). 2. Desai, et al., J. Am Chem. Soc, 116: 9420-9422 (1994). 3. Chang, et al., Pharm. Tech., 80-84 (January 1996). 4. Manning, et al., Pharm. Res., 6: 903-918 (1989). 5. Hageman, Drug Dev. Ind. Pharm, 14: 2047-2070 (1988). 6. Bell, et al., Biopolymers, 35: 201-209 (1995). 7. Zhang, et al., Pharm. Res. 12: 1447-1452 (1995). 8. Published PCT Application 98/00158 9 Published PCT Application 98/16250 10. Knepp, et al., Pharm. Res. 15 (7) 1090-1095 (1998) 11. Published application PCT 98/00157 12. Published application PCT 98/00152 13. US Patent 5,540,912 14. US Patent 5,571,525 15. US Patent 5,512,293 16. Published application of PCT 96/40049 17. Yu, et al., J. Pharm. Sci.85: 396-401 (1996) 18. Mitchell, U.S. Patent No. 5,411,951 (1995) 19. Brooks, et al., U.S. Patent No. 5,352,662 (1994) 20. Geller, L., U.S. Patent No. 3,869,549 (1975) 21. Larsen, et al., PCT publication no. WO95 / 34285 (1995). 22. Knepp, et al., J. Pharm. Sci. Tech, 50: 163-171 (1996). 23. U.S. Patent 5,614,221 24. U.S. Patent 4,594,108 25. U.S. Patent 5,300,302 26. U.S. Patent 4,588,614 U.S. Patent 4,310,516 28. U.S. Patent 5,635,213 29. EP 379,147
BACKGROUND OF THE INVENTION Peptides, polypeptides, proteins and other protein substances (eg, viruses, antibodies) collectively referred to herein as proteins, have great utility as pharmaceuticals in the prevention, treatment and diagnosis of diseases. The proteins are naturally active in aqueous environments, of this type, the preferred protein formulations have been in aqueous solutions. However, proteins are only marginally stable in aqueous solutions. Thus, protein pharmacists often have short shelf lives under ambient conditions or require refrigeration. In addition, many proteins have only limited solubility in aqueous solutions. Even when they are soluble at high concentrations, they are prone to aggregation and precipitation. Because proteins can easily degrade, the standard method for delivering such compounds has been daily injections. Proteins can be degraded via a variety of mechanisms, including deamidations of asparagine and glutamine; oxidation of methiopine and, to a lesser degree, tryptophan, tyrosine and histidine; hydrolysis of peptide bonds; disulfide bio exchange; and racemization of residues of amino acids q uirales [1 -7]. Water is a reagent in almost all of these deg radation routes. In addition, water acts as a plasticizer, which facilitates the unfolding and irreversible aggregation of proteins. Because water is a participant in almost all protein degradation pathways, the reduction of aqueous protein solution to a dry powder provides an alternative formulation methodology to enhance the stability of protein pharmacists. One approach to stabilize the proteins is to dry them using several techniques, including freeze drying, spray drying, lyophilization and drying. The dried proteins are stored as dry powders until their use is required.
A serious disadvantage of drying proteins is that one would often like to use proteins in some kind of fluidizable form. A parenteral injection and the use of medication delivery devices for sustained drug delivery are two examples of applications where one would like to use proteins in a fluidizable form. For injection, the dried proteins must be reconstituted, add additional steps which are slow and where contamination may occur, and expose the protein to potentially destabilizing conditions [7]. For drug delivery devices, protein formulations must be stable for extended periods at body temperature and maintain their ability to flow over the expected life of the device. It has been shown that protein / peptide solution formulations in non-aqueous polar aprotic solvents, such as DMSO and DMF, are stable at elevated temperatures for periods of time [8]. However, such solvent-based formulations will not be useful for all proteins, because many proteins have low solubility in these solvents. While the solubility of the protein in the formulation is less, the greater the amount of solvent to be used for the delivery of a specific amount of protein, the low concentration solutions may be useful for Injections, but may not be useful for long-term delivery at low flow rates.Proteins have been formulated for delivery ^ using perfluorodeca lin [9, 10], methosiflurane [9], high concentrations in water [11], polyethylene glycol [12], PLGA [13,14], mixtures of ethylene vinyl acetate / polyvinylpyrrodone [15], PEG400 / povidone [16] .However, these formulations were not shown to retain a uniform suspension of protein in viscous vehicle over long periods. Biologically active compounds are degraded over time in aqueous solution.The carriers in which the proteins do not dissolve, but instead are suspended, can often offer improved chemical stability. Alternatively, it may be beneficial to suspend the beneficial agent in a carrier when the agent exhibits low solubility in the desired vehicle. However, the suspensions may have poor physical stability due to settlement and agglomeration of the suspended beneficial agent. Problems with non-aqueous carriers tend to be exacerbated as the concentration of the active compound increases. It has been investigated to disperse proteins or peptides in powder in lipid vehicles to produce formulations of sustained release, parenteral [17-21]. The vehicles used were either several vegetable oils (sesame, soy, peanuts, etc.) or synthetic (for example, M ig I ol) gelled with esters of fatty acids of aluminum, such as aluminum stearates (mono-, di- or tri-) or with a polyglycerol ester. Although theoretically these vehicles could prevent solution denaturation and could protect the drug from aqueous chemical degradation, the vehicles by themselves are unstable at higher temperatures. The storage of liquid vegetable oils at body temperatures results in the formation of reactive species, such as free fatty acids and peroxides (a process, which is accelerated by the presence of traces of various metallic ions, such as copper or iron). , which can be leached from some implantab devices is). These peroxides not only adversely affect protein stability [22], but would be toxic when delivered directly to, for example, the central nervous system of a human or animal. The sustained delivery of medications has many advantages. The use of implantable devices ensures the patient's docility, because the delivery device is tamper proof. With an insert of a device, instead of daily injections, there is reduced site irritation, fewer occupational hazards for practitioners, improved cost effectiveness through decreased costs of equipment for repeated injections, reduced hazards of waste disposal, and enhanced efficacy through the release controlled, or compared to a deposit injection. The use of implantable devices for sustained delivery of a wide variety of drugs or other beneficial agents is well known in the art; standard devices are described, for example, in US Pat. 5, 034,229; 5, 057, 31 8; 5, 11, 596; and 5, 782, 396. The description of each of these patents is incorporated herein by reference. For medication delivery plans, dosing durations of up to one year are not unusual. Charitable agents, which have only therapeutic delivery rates, are the main candidates for use in im plates. When the device is implanted or stored, the settlement of the beneficial agent can occur in a liquid form. This heterogeneity can adversely affect the concentration of the beneficial agent dispensed. The solution to this problem is the size of the transplanted charitable agent deposit. The implant deposits are generally in the order of 25-250 μl, but can be up to 25 ml. Viscous formulations have been prepared using two separate components to be mixed with medication in use [23], agents
Freeze drying, lyophilization or spray drying of the active network. The drying process of the active ingredient includes additional vents, such as compounds, which are relatively unstable in aqueous solution, can be processed and filled in dosing containers, can be dried without elevated temperatures and then stored in the container. dry state, in which there are relatively few problems of stability.
The pharmaceutical formulations, in particular parenteral products, should be sterilized after being sealed in the final container and within as short a time as possible after the filling and sealing have been completed. (See, for example, Remington, Pharmaceutical Sciences, 5th ed. (1975)). Examples of sterilization techniques include thermal, or dry heat, aseptic and ionized radiation. Combinations of these sterilization procedures can also be used to produce a sterile product. There is a need to be able to deliver protein compositions to the body, which are stable at body temperatures over prolonged periods to allow long-term delivery of the protein. There is a need to be able to deliver concentrations of proteins that are effective. There is a need for a novel non-aqueous formulation, capable of homogeneously suspending proteins and dispensing such agents at body temperatures and low flow rates over prolonged periods.
Brief description of the invention The present invention provides viscous, biocompatible, non-aqueous, single-phase, stable vehicles capable of forming uniform suspensions with proteins. Viscous vehicle components comprise at least two of polymer, surfactant and? solvent. The proportions of the components will vary depending | of the molecular weight of the components and the desired viscosity of the final vehicle.
The proportions of currently preferred components are: polymer, about 5% up to about 60%; solvent, approximately 30% up to about 50%; and surfactant, approximately 5% up to about 20%. The present invention also provides stable formulations, in which the beneficial agents are uniformly suspended in viscous, biocompatible, non-aqueous, single-phase, stable vehicles. In particular, the beneficial agents are formulated in the viscous vehicles at concentrations of at least about 0.1%, depending on the potency of the beneficial agent. These stable formulations can be stored at the appropriate temperature for the beneficial agent, varying from cold to bodily temperature (approximately 37 ° C) for long periods (1 month to 1 year or more). In a preferred embodiment, the formulation comprises approximately 0. 1 to 50% (w / w) of beneficial agent, depending on the potency of the beneficial agent, the duration of treatment and the release rate for the drug delivery system. These formulations are especially useful in implantable delivery devices for long-term delivery (eg, 1 to 12 months or more) of beneficial agent at body temperature, of reference p approximately 37 ° C. Thus, the present invention also provides delivery of said proteins to the body over a prolonged period to allow long-term delivery of the protein at low flow rates of about 0.3 to 4 μl / day for approximately one period
__tf_MilM_ for delivery of 6 months and preferably, 5 to 8 μl / c during a delivery period of 3 months. | In another aspect, the invention provides methods for preparing stable, non-aqueous, biocompatible formulations of a beneficial agent in a single-phase viscous vehicle. Preferred formulations comprise approximately 0.1 to 50% (w / w) of beneficial agent depending on the potency of the beneficial agent, the duration of treatment and the release speed of the delivery system. In yet a further aspect, the invention provides methods of treating a subject suffering from a condition, which can be alleviated by the administration of a beneficial agent, said methods comprising administering to said subject an effective amount of a stable non-aqueous formulation. , which comprises at least one beneficial agent uniformly suspended in a simple viscous vehicle. An additional aspect of the invention is that viscous, single-phase, non-aqueous vehicles containing beneficial agents are chemically and physically stable over a wide temperature range for extended periods. The beneficial agents in viscous vehicles are also chemically and physically stable over a wide! temperature range for long periods. In this way, these forms are advantageous, since they can be stored and stored at temperatures below, at or above the ambient temperature for a long period. They are also suitable for use in implantable delivery devices, in which the formulation must be stable at body temperature for prolonged periods. The formulations of the present invention also remain stable when delivered from injectable drug delivery systems. It has been shown that the beneficial agents exhibit zero order release rates when delivered from implantable drug delivery systems at very low flow rates over extended periods.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the stability of hGH formulations of the present invention as determined at 37 ° C by reverse phase HPLC. Figure 2 shows the stability of hGH formulations of the present invention as determined at 37 ° C by size excision chromatography. Figure 3 shows the average release rate (μl / day) of 10% (w / w) of spray-dried lysozyme in formulations of the present invention. Figure 4 shows the average release rate (μl / day) of 10% (w / w) of hG H dried by vehicle spray of glycerol mono aurate / lauryl lactate / polyvinylpyrrolidone. Figure 5 shows the average release rate (μg / day) of 10% lysozyme in a lauryl alcohol / polyvinylpyrrolildone vehicle. Figure 6 shows the average release rate (μg / day) of 25% isozyme in a glyceryl monolaurate / lauryl lactate / polyvinylpyrrolidone vehicle.
Figure 7 shows the average release rate ¡(μg / day) of 33% lysozyme in a lauryl glycerol monolaurate / polyvinylpyrrolidone monolaurate vehicle. Figure 8 shows the average release rate (μg / day) of 45% lysozyme in a vehicle of glycerol monolaurate / lauryl lactate / poly ivinylpyrrole idone.
DETAILED DESCRIPTION OF THE INVENTION The present invention is led to the unexpected discovery that uniformly suspending beneficial agents in 1 viscous, biocompatible, single-phase, non-aqueous vehicles results in stable formulations, which can be delivered to body temperature over a prolonged period at low flow rates. The previously known formulations of beneficial agents, which are buffered aqueous or non-aqueous solutions, which may or may not contain excipients, do not provide formulations that can be uniformly dispensed at body temperatures at low flow rates over a prolonged period without exhibiting unacceptable amounts. of ag regation or degradation of the formulation. The formulations currently claimed stabilize beneficial agents and can be stored at the appropriate temperature for the beneficial agent. Temperatures can vary from cold (without exceeding 8 ° C) to corporal (approximately 37 ° C) for extended periods. These formulations are especially useful in implantable delivery devices for long-term delivery (eg, 1 to 1 2 months or more) of medicament at low flow rates and at body temperature, preferably about 37 ° C. Standard benefit agent formulations consist of dilute aqueous or non-aqueous solutions or suspensions. Drug stability is usually achieved by varying one or more of the following: pH, type of buffer, ionic strength, excipients (EDTA, ascorbic acid, etc.). For these formulations, degradation pathways requiring water (hydrolysis, deamidation, racemization) can not be fully stabilized. In the present invention, it was shown that beneficial agents formulated in viscous, single-phase, biocompatible, non-aqueous vehicles containing, for example, polyvinylpyrrolidone, vinyl acetate and / or polyoxyethylenepolyoxypropylene block copolymers are chemically and physically stable. The viscosity of the formulation will depend on a variety of criteria, including the potency and concentration of beneficial agent, and the process by which the formulation is prepared. The viscosity of the formulation can be chosen so that the desired amount of beneficial agent is delivered over the desired period. The invention also consists of viscous, biocompatible, single-phase, non-aqueous vehicles capable of uniformly suspending beneficial agents and formulations containing at least one beneficial agent uniformly suspended in said viscous vehicle. The invention also consists of formulations containing alomenes un! Beneficial agent uniformly suspended in a viscous vehicle, biocompatible, single phase, non-aqueous, said formulations are stable for a prolonged period at body temperatures, and are capable of delivering said beneficial agents uniformly at low flow rates. The discovery consists of the understanding that viscous, non-aqueous, stable vehicles improve the stability of the beneficial agents in a wide range of formulation conditions, including concentration, high temperatures and duration of stable formulation. , making it possible in this way, the delivery of beneficial agents in long-term implantable devices that would not otherwise be feasible.
Definitions As used herein, the following terms have the following meanings: The term "chemical stability" means that an acceptable percentage of degradation products produced by chemical routes, such as oxidation, deamidation or hydrolysis, is formed. In particular, a formulation is considered chemically stable if no more than about 35% decomposition products are formed after 2 months at 37 ° C. The term "physical stability" means that an acceptable percentage of aggregates (eg, dimers, trimers, and larger forms) is formed by the beneficial agent. For the formulation (viscous vehicle and beneficial agent) this term means that the formulation retains stability, ability to flow, the ability to uniformly dispense the beneficial agent. In particular, a form ulation is
- ^ y ^ considered physically stable if no more than about 15% of ag is formed after two months at 37 ° C. The term "stable formulation" means that at least about 65% of chemically beneficial and physically stable agent remains after two months at 37 ° C (or equivalent conditions at a high temperature). Particularly preferred formulations are those which retain at least about 80% chemical beneficial agent and physically stable under these conditions. Especially preferred stable formulations are those which do not exhibit degradation after sterilizing irradiation (eg, ga mm a, beta or electron beam). The term "beneficial agent" means peptides, proteins, nucleotides, hormones, viruses, antibodies, etc. which comprise polymers of amino acid residues or nucleic acids. These beneficial agents are generally detectable in water and generally stable as a dry powder at elevated temperatures. The portions produced, synthetically, derived naturally or produced recombinantly, are included in this term. The term also includes lipoproteins and modified post-translational forms, for example, glycosylated proteins. Analogs, derivatives, agonists, antagonists and pharmaceutically acceptable salts of any of these are included in this term. The term also includes proteins and / or protein substances, which have D-amino acids, modified amino acids, derivatives or that do not occur naturally in the D or L configuration and / or peptom ine units as part of their structure. The term "protein" will be used in the present invention. The term also means that the beneficial agent is present in the solid state, for example, powder or crystalline. The term "excipient" means a more or less inert substance in a formulation that is added as a diluent or vehicle or to give shape or consistency. The excipients are distinguished from solvents, such as ETOH, which are used to dissolve drugs in formulations. The excipients include nonionic surfactants, such as polysorbates, which are used to solubilize medicaments in formulations; preservatives, such as benzyl alcohols or methyl or propyl parabens, which are used to prevent or inhibit microbial growth; chelating agents; flavoring agents; and other pharmaceutically acceptable formulation auxiliaries. I The term "viscous vehicle" means a vehicle with a viscosity in the range of approximately 1,000 to 10,000,000 poises. The term includes Newtonian and non-Newtorian materials. Vehicles with a viscosity of approximately 10,000 to
250,000 poises. The formulations of this invention can uniformly expel beneficial agents suspended in the viscous vehicle from implantable drug delivery devices. The formulations exhibit a cutting speed at the output of said devices of 1 z 1 x 10"7 reciprocal seconds, preferably an output cutting speed of 1 x 10" 2 to 1 x 105 reciprocal seconds.
The term "simple phase" means a solid, semi-solid or liquid homogenous system that is both physically and chemically uniform throughout, as determined by differential scanning calorimetry (DSC). The DSC scan should show a peak indicative of a simple phase. The term "biocompatible" means a property or characteristic 5 of a viscous vehicle to disintegrate or decompose, over a prolonged period, in response to the biological environment in the patient, by one or more physical or chemical degradation processes, for example, by action enzymatic, oxidation or reduction, hydrolysis (proteolysis), displacement, for example, ion exchange, or
dissolution by solubilization, emulsion or micelle formation, and said material is then absorbed by the surrounding body and tissue or is otherwise dissipated therefrom. The term "polymer" includes polyesters, such as PLA (polylactic acid) [having an inherent viscosity in the range of
approximately 0.5 to 2.0 iv] and PLGA (polylactic polyglycolic acid) [having an inherent viscosity in the range of about 0.5 to 2.0 iv], pyrrolidones, such as polyvinylpyrrolidone (having a molecular weight range of about 2,000 to 1,000,000), esters or ethers of unsaturated alcohols, such as vinyl acetate and
polyoxyethylenepolyoxypropylene block copolymers (exhibiting a high viscosity at 37 ° C), such as Pluronic 105. The currently preferred polymer is polyvinylpyrrolidone. The term "solvent" includes carboxylic acid esters, such as lauryl lactate, polyhydric alcohols, such as glycerin,
polymers of polyhydric alcohols, such as polyethylene glycol, (having
-fi l? T - - ™ »> - * J - -. - • - - B? _Ué a molecular weight of about 200 to 600), fatty acids, such as oleic acid and octanoic acid, oils such as rici oil, propylene carbonate, lauryl alcohol or poly alcohol esters rich, such as triacetin acetate. The currently preferred one is lauryl lactate. The term "surfactant" includes polyhydric alcohol esters, such as glycerol monolaurate, ethoxylated castor oil, polysorbates, esters or ethers of saturated alcohols, such as myristyl lactate (Ceraphyl 50) and polyoxyethylenepolyoxypropylene block copolymers, such as Pluronic. Monolaurate and glycerol and polysorbates are currently preferred. The term "antioxidant" means a pharmaceutically acceptable auxiliary for stabilization of the beneficial agent against degradation, such as oxidation. Antioxidants include, but are not limited to, tocopherol (vitamin E), ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene and propyl gallate. A preferred antioxidant depends on the solubility and efficiency of the antioxidant to protect against degradation or chemical change of the beneficial agent in the preferred vehicle. Currently, ascorbyl palm itato is preferred.
FORMULATION PREPARATION The present invention is directed to viscous, biocompatible, simple phase, nonaqueous, stable vehicles capable of suspending beneficial agents and uniformly dispensing said agents.
......... ____.._.
beneficial agents at body temperatures at low flow rates over a prolonged period. The present invention is also directed to formulations containing suspended beneficial agents (uniformly in such viscous, biocompatible, single phase vehicles, which are stable for extended periods at body temperatures.) Examples of beneficial agents that can be formulated using the present invention, include those peptides or proteins which have biological activity or which can be used to treat a disease or other pathological condition.But they are not limited to, adrenocorticotropic hormone, angioensina I and II, atrial natriuretic peptide, bombesin, radicinina, calcitonin, cerebellína, dynorphin N, alpha and beta endorphin, endothelin, enkephalin, epidermal growth factor, fertirelin, releasing peptide follicular gonadotropin, galanin, glucagon, GLP-1, gonadorelin, gonadotropin, goserelin, releasing peptide growth hormone, histrelin, human growth hormone, insulin, interferons, leuprolide, LHRH, motilin, nafarerlína, neurotensin, oxytocin, relaxin, somatostatin, substance P, tumor necrosis factor, triptorelin, vasopressin, growth hormone, nerve growth factor, blood coagulation factors, ribozymes and antisense oligonucleotides. Analogs, derivatives, antagonists, agonists and pharmaceutically acceptable salts of the foregoing can also be used. The beneficial agents useful in the formulations and methods of the present invention can be used in the form of a salt, preferably a pharmaceutically acceptable salt. Useful salts are known to those skilled in the art and include salts with inorganic acids, organic acids, inorganic bases or organic bases. Beneficial agents that are not readily soluble in non-aqueous solvents are preferred for use in the present invention. One skilled in the art can easily determine which compounds will be useful on the basis of their solubility. The amount of beneficial agent may vary depending on the potency of the compound, the composition to be treated, the solubility of the compound, the expected dose and the duration of administration. (See, for example, Gilman, et al., The
Pharmacological Basis of Therapeutics, 7th ed. (1990) and Remington, Pharmacological Sciences, 18th ed. (1990), the descriptions of which are incorporated herein by reference.) Unexpectedly, it has been found that using a viscous, biocompatible, single-phase, non-aqueous, stable vehicle increases the stability of the beneficial agent. For example, as seen in Figures 1 and 2, it was found that human growth hormone (hGH) was stable at 37 ° C over 12 weeks in polyvinylpyrrolidone / PEG formulations; Pluronic; and glycerol monolaurate / lauryl lactate / polyvinylpyrrolidone. Figure 1 shows the stability results using reverse phase HPLC. Figure 2 shows the stability results using size exclusion chromatography. In general, viscous, biocompatible, single-phase, nonaqueous, stable vehicles can be prepared by combining the dry ingredients (low moisture content) in a dry box or, under other dry conditions, and mixing them at elevated temperature, preferably about 40 to about 70 ° C, to allow them to liquefy. The liquid vehicle is allowed to cool to room temperature. Differential scanning calorimetry was used to verify that the vehicle was in the simple phase. The final moisture content of the viscous vehicle was < 2% . In general, the stable formulations of the present invention can be prepared by combining the carrier and benefit agent under dry conditions and mixing them under vacuum at elevated temperature, preferably about 40 to about 70 ° C, to disperse the beneficial agent uniformly through the vehicle. icle Allow the formulation to cool to room temperature. It has been found that drying the beneficial agent prior to formulation intensifies the stability of the formulation. It has also been found that adding antioxidants, such as tocopherol, ascorbic acid, ascorbyl palm itoate, butylated hydroxyanisole, butylated hydroxytoluene and propyl gallate, reduces the formation of degradation products (eg, unstable chemical intermediates *) during sterilization.
Methodology We have found that formulations of beneficial, non-aqueous, stable agents can be prepared by utilizing viscous vehicles by combining the ingredients for the viscous vehicle under dry conditions and by using the same ingredients.
mix them at elevated temperature to allow them to liquefy and form a simple phase. Once the single-phase viscous vehicle is formed, the vehicle is allowed to cool to room temperature. The beneficial agent is added with mixing at elevated temperature; under vacuum to disperse it evenly in the viscous vehicle. We have tested these formulations of beneficial agents, for example, hGH formulations, for stability when subjected to tests of accelerated aging. The results show that these forms remained stable over long periods. We have tested formulations of beneficial agents, for example, human growth hormone and lysozyme, for stability by suspending them in a variety of viscous, single-phase, non-aqueous vehicles prepared in accordance with the present invention, subjecting them then to accelerated aging. at elevated temperatures. The stability of the formulations was measured. The results of these studies show that these formulations were stable under conditions that approximate or exceed storage for one year at 37 ° C. We have also tested agent formulations. charities prepared as described herein, for stability after 2.5 meg arads of gamma irradiation. The results show that these formulations remained chemically and physically stable after such irradiation.
The methods
_a¿_ The following methods were used to perform the studies in the following Examples.
1 . Prepare protein powders Human growth hormone (obtained, for example, from
BresaGen Lim ited, Adelaide, Australia) The active agent was reconstituted in deionized water. The solution containing the active agent was exchanged as a buffer using an Amicon Diaflo® ultrafiltration membrane (molecular weight cutoff of 1,000,000). The diafiltered active agent solution was spray-dried using a Yamato spray mini-dryer. The powder was collected in a collection container through a cyclone trap. All handling of the spray-dried powder took place in a • dry box evacuated with nitrogen. The generated dust was analyzed by particle size and distribution, moisture content, protein content and stability by reverse phase chromatography and exclusion per year. It is known that the conformation of some proteins can be stabilized by the addition of a sugar (such as sucrose or mannitol) or a polyol (such as ethylene glycol, glycerol, glucose and dextran).
2. Preparation of viscous vehicles We have found that viscous, biocompatible, single-phase, stable vehicles can be prepared by combining the ingredients and mixing them at elevated temperatures to allow them to liquefy and form a simple phase. A differential scanning calorimetry scan showed a peak, indicative of a simple phase. The mixing was completed under vacuum to remove trapped air burbtffas produced by the powders. The mixer was a dual-blade blade mixer (D. I.T.), Which runs at a speed of about 40 rpm. Higher speeds may be used but are not required. If a three-component viscous vehicle is prepared, the solvent portion of the vehicle was added to the heated bowl of the mixer first, followed by the surfactant. The polymer was added to the latter, and the ingredients were mixed until a solution resulted (single phase). The vacuum was applied during mixing to remove the air bubbles. The solution was dispensed from the bowl while it was at elevated temperature and allowed to cool to room temperature. Upon cooling, the vehicle exhibited increased viscosity. One and two component gels were made using the same process.
3. Preparation of beneficial agent formulations To prepare the formulation, the single phase viscous vehicle was heated and then mixed under vacuum with a heavy amount of beneficial agent. The beneficial agent and the single phase viscous vehicle were mixed in the same manner as the vehicle was prepared, using a dual-blade blade mixer (or other similar mixer). The mixing speed was between 40 and 120 rpm for about 15 minutes or until a uniform dispersion was obtained. The resulting mixture was removed from the mixer, sealed in a dry container, and allowed to cool to room temperature.
4. Preparation of Deposits Deposits of implantable drug delivery devices (as described in US Patent Application Serial No. 08 / 595,761, incorporated herein by reference) were filled with the appropriate hG H formulation. The formulation was filled in titanium tanks with a polymer plug blocking each end. The filled reservoir was then sealed in a poly-laminated bag and placed in a stability testing oven. It should be noted that the formulations in the tanks of these devices are completely isolated from the outside environment.
. Reverse phase HPLC (RP-HPLC) All stability samples of hGH were assayed for protein content and chemical stability by reverse phase chromatography (RP-H PLC). The analyzes were performed on a Hewlett Packard HP-1090 system with a refrigerated auto-sampler (4 ° C). The chromatographic conditions used are listed below.
TABLE 1 RP-HPLC chromatographic conditions Description Parameter Column J .T. Bker-C 1 8, 4.6x250 mm Flow rate 1 .0 ml / min Detection 214 nm Mobile phase A: 0.1% TFA in water B: 0. 1% TFA in acetonitrile Gradient time% A% B 0 65 35 5 50 50 45 35 65 50 30 70 55 35 35
A standard reference solution of hGH was prepared and its protein content was calculated from the absorbance measurement at 280 nm. Three dilutions of this solution were run, representing 80%, 1,005 and 120% of the expected concentration of hGH in the samples in duplicate at the beginning and at the end of each run, and were used to calculate the total protein content of the samples. m uestras
6. Size exclusion chromatography (S EC) All stability samples of hG H were assayed for protein content and degradation products of high molecular weight medium size exclusion chromatography. The analyzes were performed on a Hewlett Packard H P-1 090 system with a refrigerated auto-sampler (4 ° C). The chromatographic conditions used are listed below.
TABLE 2 SEC chromatography conditions Description Parameter Column TSK-2000SWXL Flow rate 0.5 ml / min Detection 214 nm Mobile phase 25 mM sodium phosphate, 100 mM sodium chloride, pH 7.0
A reference standard solution of hGH was prepared and its protein content was calculated from the abnorbance measurement at 280 nm. Three dilutions of this solution were run, representing 80%, 1,005 and 1 20% of the expected concentration of hGH in the samples, by d uplicate at the start and at the end of each run, and were used to calculate the content of total protein of the samples. The amount of high molecular weight degradation products was calculated by area normalization. The following examples are offered to illustrate this invention and will not be construed in any way as limiting the scope of this invention.
EXAMPLE 1 Preparation of viscous, single-phase, non-aqueous vehicles Viscous, single-phase, non-aqueous vehicles can be prepared as follows and are shown in the table below A. Glycerol monolaurate (Danisco Ingredients, New Century, kansas )
(25 g) was dissolved in lauryl lactate (ISP Van Dyk I nc. J Bellevílle,
NJ) (35 g) at 65 ° C. polyvinylpyrrolidone C30 was added (BASF, Mount
Olive, NJ) (40 g) and the mixture was stirred at approximately 40 rpm in a dual-blade blade mixer (D.I.T) until a single phase was reached. The trapped air bubbles were removed by applying vacuum to the mixing chamber. The single phase vehicle was dispensed from the mixer and allowed to cool to room temperature. B. Glycerol monolaurate (Danisco I ngredients, New Century, Kansas)
(25 g) was dissolved in lauryl lactate (ISP Van Dyk Inc., Bellevílle, NJ)
(35 g) at 65 ° C. Polyvinylpyrrole idona C 1 7 was added (BASF, Mount
Olive, NJ) (40 g) and the mixture was stirred at approximately 40 rpm in a dual-blade blade mixer (D. I .T.) Until a single phase was reached. Trapped air bubbles were removed when vacuum was applied to the mixing chamber. The single phase vehicle was dispensed from the mixer and allowed to cool to room temperature. C. Polyvinylpyrrolidone C30 (BASF, Mount Olive, NJ) (50 g) was dissolved in polyethylene glycol 400 (Carbide Unit) (50 g) at a temperature of approximately 65 ° C until a simple phase solution formed. The single phase vehicle was dispensed from the mixer and allowed to cool to room temperature. D. Polyvinylpyrrolidone C 1 7 (BA; SF \ Mount Olive, NJ) (50 g) was dissolved in polyethylene glycol 400 (Union Carbide) (50 g) at about 65 ° C until a simple phase solution formed. The single phase vehicle was dispensed from the mixer and allowed to cool to room temperature. E. Polyvinylpyrrolidone C 1 7 (BASF, Mount Olive, NJ) (50 g) was dissolved in castor oil (Spectrum, Gardena, CA) (50 g) at about 65 ° C until a simple phase solution formed. The single phase vehicle was dispensed from the mixer and allowed to cool to room temperature. F. Polyvinylpyrrolidone C 1 7 (BASF, Mount Olive, NJ) (50 g) was dissolved in octanoic acid (Spectrum, Gardena, CA) at about 65 ° C until a simple phase solution formed. The sim ples vehicle was left out of the mixer and allowed to cool to room temperature. G Polyvinylpyrrolidone C 1 7 (BASF, Mount Olive, NJ) (50 g) was dissolved in oleic acid (S pectrum, Gardena, CA) at about 65 ° C until a simple phase solution formed. The simple phase vehicle was dispensed from the mixer and allowed to cool to room temperature. H. Polyvinylpyrrolidone C 1 7 (BASF, Mount Olive, NJ) (35%) was dissolved in glycerin (Baker, NJ) (65%) at about 65 ° C until a simple phase solution formed. The simple phase vehicle was dispensed from the mixer and allowed to cool to room temperature. Cremophor EL (ethoxylated castor oil) (BASF, Mount Olive, NJ) (5%) was dissolved in castor oil (Spectrum, Gardena, CA) (70%) and added polyvinylpyrrolidone C 1 7 (BASF, Mount Olive , NJ) (25%) and dissolved upon mixing at approximately 40 rpm to form a single phase vehicle. The simple phase vehicle was dispensed from the mixer and allowed to cool to room temperature. Pluronic 105 (BASF, Mount Olive, NJ) was heated to about 65 ° C with mixing until melted. The simple phase vehicle was dispensed from the mixer and allowed to cool to room temperature.
TABLE 3 Proportions of components Component Viscosity at low
Solvent Surfactant Polymer Proportion of cutting speed (poíses)
PVP GML LL 53: 5: 42 PVP GML LL 55:10:35 50,000
PVP GML LL 50:15:35 7,000
PVP LA 60:40 PVP Ceraphyl 50 LA 60:10:30 PVP __. Oleic acid 50:50 30,000
PVP --- Octanoic acid 55:45 7,000
PVP Polysorbate 80 --- 50:50 PVP ___ PEG 400 50:50 PVP Castor oil --- 50:50 --- Pluronic 105 --- 100 1,000,000
PVP Glycerin 50:50 5,000
Where: GML = glycerol monolaurate LL = lauryl lactate PVP = polyvinylpyrrolidine C30 LA = lauryl alcohol PEG = polyethylene glycol 400 EXAMPLE 2 Preparation of hGH
A. Preparation by spray drying Lyophilized hGH was reconstituted (BresaGen Limited, Adelaide,
Australia) in 150 ml of deionized water. This stock solution contained 1050 mg of hGH. Buffer exchange was achieved using an Amicon Diaflo® ultrafiltration membrane (10,000 molecular weight cut). The ultrafiltration cell was connected to an auxiliary reservoir containing 5Mm of phosphate buffer (Ph 7). The volume of fluid in the cell, as well as the concentration of hGH, remained constant as the excipients were replaced by phosphate buffer. The diafiltered protein solution (concentration of protein in the solution of approximately 2%) was spray-dried using a Yamato spray mini-dryer. The settings of the spray dryer were as follows: suction pressure constantly adjusted to 1.3 kgf / c 2, inlet temperature 120 ° C, solution flow rate 2.5 (approximately 3 ml / min). The powder was collected in a collection vessel through a cyclone trap. All handling of the spray-dried powder took place in a dry box evacuated with nitrogen (% RH: 1-4%). The water content of the suspension vehicles is shown in the following table.
TABLE 4 WATER CONTENT OF SUSPENSION VEHICLES Vehicle Water content Water content of vehicle vehicle at T 0 in 12 weeks at 37 ° C% w / w% w / w Pluronic 105 0.25 0.4 GML / LL / PVP 1.5 1.3 RRP / PEG 2.0 2.0
Where: GML = glycerol monoaurate LL = lauryl lactate PVP = polyvinylpyrrolidine C30 PEG = polyethylene glycol 400
EXAMPLE 3 Preparation of hGH formulation A portion of the single phase viscous vehicle was weighed (9 g) and heated to 60 ° C. HGH was added (BresaGen Limited, Adelaide, Australia)
(1 g) to the vehicle and mixed for 15 minutes. The mixing was completed under vacuum to remove air bubbles added from the powder.
Approximately 10 mg of the spray dried hGH powder was weighed (the content of hGH in the powder was recalculated based on the determined water and salt content) and mixed with 100 μl of the vehicle at 55-65 ° C (3 samples per each vehicle). Special care was taken while mixing the powder in the suspension vehicle to achieve maximum uniform particle dispersion in the vehicle. 1 All the steps were done in a dry box. The resulting suspension was dissolved with 10 ml of buffer and release rate and analyzed by size exclusion and reverse phase chromatography. HGH spray-dried powder was used as a control.
TABLE 5 Stability of suspensions of hGH at 37 ° C as measured by size exclusion chromatography Time Dust Dried by Suspension of Suspension of Suspension weeks spray-80 ° C PVP / PEG 400 GML / LL / PVP Pluronic 105% LS % LS% LS% LS
0 96 ± 1 88 ± 6 92 ± 2 87 ± 7 1 99 ± 8 81 ± 2 94 ± 3 93 ± 3
2 99 ± 3 83 ± 1 97 ± 1 94 ± 1
3 97 ± 1 84 ± 2 95 + 2 95 + 3
4 95 + 2 82 + 8 94 ± 4 93 ± 5
7 95 + 4 76 ± 3 93 ± 4 88 ± 2
1 2 97 ± 4 79 ± 3 97 ± 1 95 ± 6
Each data represents the average ± the relative standard deviation of three individual samples taken from three separate bottles.
TABLE 6 Stability of suspensions of hGH at 37 ° C as measured by reverse phase chromatography Time Dust Dried by Suspension of Suspension of Week Suspension aspersion-80 ° C PVP / PEG 400 GML / LL / PVP Pluronic 105% LS% LS% LS% LS 0 104 ± 1 99 ± 3 99 ± 2 89 ± 7 1 104 ± 8 75 + 2 98 ± 3 96 ± 6 2 104 ± 4 73 ± 3 95 ± 1 96 ± 1 3 104 ± 2 78 ± 4 97 + 3 97 ± 4
4 100 + 2 74 ± 10 93 ± 4 96 + 4
7 108 + 5 72 ± 4 96 ± 2 94 + 2
9 102 ± 3 66 ± 3 92 ± 3 93 ± 2
12 101 ± 2 66 ± 1 89 + 2 92 + 5
Each data represents the average ± the relative standard deviation of three individual samples taken from three separate bottles.
EJ EM PLO 4 Preparation of deposits Release rate profiles The deposition systems of drug delivery devices (as described in US patent application Ser. No. 08/595, 761, incorporated herein by reference) were each assembled with an osmotic motor, piston and speed control membrane. The tanks were filled with the appropriate amount of viscous vehicle formulation and plugged with a flow plug. The systems were placed in a water bath at 37 ° C and allowed to form for a prolonged period. The material released was sampled twice a week. Assays for released material were completed using reverse phase HPLC. The resulting concentrations of beneficial agent for each system were converted to free capacity per day. The beneficial agent was found to have a zero order release from the implantable drug delivery device, as shown in Figures 3 to 8.
EJ EM P LO 5 Stability of hGH in viscous, non-aqueous vehicle formulations The formulations of 10% w / w of hGH in vehicle were prepared as described and placed in flasks. The formulations were subjected to accelerated aging by storing them at elevated temperatures and times shown in the table below in a temperature controlled oven.
TABLE 7 Vehicle Time (h) Temperature% LS per SEC% LS by RP-HPLC
Pluronic 105"5 50 ° C ~ 98 + 3 101 ± 3
Pluronic 105 1 50 ° C 98 ± 3 101 + 4
Pluronic 105 2 50 ° C 100 + 1 1¡02 + 3
Pluronic 105 4 50 ° C 101 + 3 105 + 3
GML / LL / PVP 0 65 ° C 99 ± 3 101 + 3
GML / LL / PVP 1 65 ° C 93 ± 6 97 ± 6
GML / LL / PVP 2 65 ° C 91 + 5 95 ± 5
GML / LL / PVP 4 65 ° C 95 ± 3 98 + 3
Each data represents the mean ± the relative standard deviation of three individual samples taken from three separate bottles. The results, presented in the following table, demonstrate that these formulations are capable of maintaining the stability of hGH in each case. In each case, at least 70% hGH was retained.
TABLE 8 Retrieval of hGH from non-aqueous suspensions Vehicle% LS by RP-HPLC% by HPLC exclusion by size PVP / PEG 400 99 + 3% 88 + 6% GML / LL / PVP 99 ± 2% 92 ± 2% Pluronic 105 89 ± 7% 87 ± 7%
"?
Each data represents the average ± the relative standard deviation of three individual samples taken from three separate bottles. % LS or% brand strength = (measured protein content '+ theoretical protein content) x 1 00% Modification of the modes described above to perform various embodiments of this invention will be apparent to those of skill in the art, following the teachings of this invention as set forth herein. The examples described above are not limiting, but simply exemplary of this invention, the scope of which is defined by the following claims.
Claims (38)
- RE IVI N DI CATIONS 1 A viscous vehicle, biocompatible, simple phase, non-aqueous, stable, able to suspend beneficial agents and homogeneously dispense said beneficial agent over a prolonged period at body temperature and at low flow rates.
- 2. The vehicle of claim 1, comprising two components selected from the group consisting of solvent, surfactant and polymer, wherein the two components are not of the same type.
- 3. The vehicle of claim 1, comprising at least two components selected from the group consisting of solvent, surfactant and polymer, wherein the components are not of the same type.
- 4. The vehicle of claim 1, which comprises three components selected from the group consisting of solvent, surfactant and polymer, wherein the components are not of the same type.
- 5. The vehicle of claim 2 or 4, wherein said solvent is selected from the group of carboxylic acid esters, polyhydric alcohols, polyhydric alcohol polymers, fatty acids, oils, propylene carbonate, lauryl alcohol and esters of polyhydric alcohols.
- 6. The vehicle of claim 2 or 4, wherein said surfactant is selected from the group of polyhydric alcohol esters, non-ethoxy side oil, polysorbates, esters or ethers of saturated alcohols and polyoxyethylenepolyoxypropylene block copolymers. .
- 7. The vehicle of claim 2 or 4, wherein said polymer is selected from the group of polyesters, pyrrolidones, esters, esters of unsaturated alcohols, and polyoxyethylenepolyoxypropylene block copolymers. The vehicle of claim 2, wherein the proportions of the components are in the range of 40:60 to 60:40. The vehicle of claim 4, wherein the proportions of the components are in the range of about 30% to about 50% for solvent, about 5% to about 20% for surfactant, and about '5% to about 60% for polymer. The vehicle of claim 4, wherein the polymer is polyvinyl pyrrolidone, the surfactant is gml, and the solvent is lactate laudel. 11. The vehicle of claim 4, wherein the polymer is polyvinyl pyrrolidone, the surfactant is polysorbate and the solvent is lauyl lactate. 12. The vehicle of claim 1, which comprises an antioxidant. 13. The vehicle of claim 12, wherein said antioxidant is selected from the group consisting of tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene and propyl gallate. 14. A stable, non-aqueous, viscous protein formulation comprising: a) at least one beneficial agent, and b) a viscous, biocompatible, single-phase, non-aqueous vehicle, said formulation is capable of being uniformly dispensed over a period of time. prolonged at a low flow rate. A non-aqueous formulation comprising at least one beneficial agent uniformly suspended in a viscous, biocompatible, single-phase, non-aqueous vehicle, said formulation can be delivered from an implantable drug delivery system, so that the cutting speed of the formulation is between about 1 and 1 x 1 0"7 reciprocal seconds 16. The formulation of claim 14, wherein said formulation is stable at body temperature for prolonged periods. 14, which comprises at least about 0. 1% (w / w) of beneficial agent 1 8. The formulation of claim 14, which comprises at least about 10% (w / w) of beneficial agent. 19. The formulation of claim 14, wherein said beneficial agent is selected from the group consisting of peptide, protein, nucleotide, hormone, virus or antibody. ation 1 9, wherein said beneficial agent is a protein. twenty-one . The formulation of claim 14, which is stable at 65 ° C for at least about 2 months. 22. The formulation of claim 1, which is stable at 37 ° C for at least about 3 months. 23. The formulation of claim 14, which is stable at 37 ° C for at least about one year. The formulation of claim 1, which is adapted for use in an implantable drug delivery device. The formulation of claim 14, wherein said carrier is selected from the group consisting of solvent, surfactant and polymer. 26. The formulation of claim 14, wherein said carrier comprises an antioxidant. 27. The formulation of claim 14, comprising a beneficial agent, which has been dried at a low moisture content before incorporation into said formulation. 28. The formulation of claim 14, which is stable after sterilization. 29. A method for preparing the single-phase, stable, viscous vehicle of claim 1, comprising the steps of (1) mixing the carriers at elevated temperature under dry conditions to allow them to liquefy, and (2) ) allow the liquid from step (1) to cool to room temperature. 30. A method for preparing the stable formulation of claim 14, which comprises combining the single-phase viscous vehicle and beneficial agent under dry conditions and mixing them under vacuum at elevated temperature to uniformly disperse the beneficial agent in the vehicle and allow the formulation to cool to room temperature. 31 The method of claim 30, wherein at least about 0. 1% (w / w) of beneficial agent is suspended in said vehicle. 32. The method of claim 30, wherein at least about 10% (w / w) of beneficial agent is suspended in said vehicle. 33. A method for treating a subject suffering from a condition, which can be alleviated by the administration of a beneficial agent, comprising administering to said subject a therapeutically effective amount of the formulation of claim 14. 34. The method of claim 33, wherein said administration is parenteral administration. 35. The method of claim 33, wherein said administration is continuous long-term administration. 36. The method of claim 33, wherein said administration is achieved by the use of an implantable drug delivery system. 37. The method of claim 33, wherein said day administration continues for a period selected from the group consisting of about 3 months, about 6 months and about 12 months. 38. The method of claim 37, wherein said daily administration is achieved using an im plantable drug delivery system.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/119,170 | 1999-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA01008006A true MXPA01008006A (en) | 2002-05-09 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7258869B1 (en) | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle | |
CA2361424C (en) | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles | |
US8372424B2 (en) | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles | |
EP1610765B1 (en) | Non-aqueous single phase vehicles and formulations utilizing such vehicles | |
MXPA01008006A (en) | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |